Ares Financial Consulting’s Xenon Pharmaceuticals XENE Stock Holding History

Ares Financial Consulting’s Portfolio XENE Stock Details XENE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$724	Buy	+12	New	+$666	﹤0.01%	1051

Other funds holding XENE

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return

Jupiter Topco New York $245B AUM

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Ares Financial Consulting's XENE Position: Q2 2026 in Review

Ares Financial Consulting opened a new position in Xenon Pharmaceuticals (XENE) in Q2 2026: 12 shares worth $724. The stake represents ﹤0.01% of the portfolio and ranks #1051 among its holdings.

315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

Ares Financial Consulting held 12 shares of Xenon Pharmaceuticals worth $724 as of Q2 2026.
Xenon Pharmaceuticals was a new Ares Financial Consulting position in Q2 2026.
Xenon Pharmaceuticals made up ﹤0.01% of Ares Financial Consulting's portfolio in Q2 2026, its #1051 holding.
315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Ares Financial Consulting's 13F filing for Q2 2026, filed 9 Jul 2026.